Service platform for the search for antibody parts with therapeutic and diagnostic potential (Q78283): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Created claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The project “Service platform for the search for antibodies with therapeutic and diagnostic potential” (hereinafter:The project) implemented by Pure Biologics...) |
||
| Property / summary | |||
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The project “Service platform for the search for antibodies with therapeutic and diagnostic potential” (hereinafter:The project) implemented by Pure Biologics Sp. z o.o. is the development of an innovative platform for the production and production of antibodies based on phage display.As a result of the project, the product will be implemented in the market for product innovation which has been significantly improved in relation to the available solutions for the detection of antibodies.The capacity to recognise a wide range of antigens allows them to be at the centre of the development of medicines and medical diagnostics.Antibodies specifically address the disease location, minimising the side-effects of the treatment.They are also used in diagnostic tests as an analyte.Rapid diagnosis to monitor patient status is essential for modern medicine.The number of tests performed at home or in the laboratory is constantly increasing, which translates into increased demand for new molecules that recognise the antigens.The Pure Bioologtics already launched in 2012 the PureSelect Platform to seek antibody based on a phase presentation technique as an alternative to immunising animals.The experience gained over the years has identified areas for improvement in order to respond to changing market demands and has led us to develop a new product with increased functionality and efficiency that will ensure our competitiveness and market share. (English) | |||
| Property / summary: Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The project “Service platform for the search for antibodies with therapeutic and diagnostic potential” (hereinafter:The project) implemented by Pure Biologics Sp. z o.o. is the development of an innovative platform for the production and production of antibodies based on phage display.As a result of the project, the product will be implemented in the market for product innovation which has been significantly improved in relation to the available solutions for the detection of antibodies.The capacity to recognise a wide range of antigens allows them to be at the centre of the development of medicines and medical diagnostics.Antibodies specifically address the disease location, minimising the side-effects of the treatment.They are also used in diagnostic tests as an analyte.Rapid diagnosis to monitor patient status is essential for modern medicine.The number of tests performed at home or in the laboratory is constantly increasing, which translates into increased demand for new molecules that recognise the antigens.The Pure Bioologtics already launched in 2012 the PureSelect Platform to seek antibody based on a phase presentation technique as an alternative to immunising animals.The experience gained over the years has identified areas for improvement in order to respond to changing market demands and has led us to develop a new product with increased functionality and efficiency that will ensure our competitiveness and market share. (English) / rank | |||
Normal rank | |||
Revision as of 09:11, 4 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Service platform for the search for antibody parts with therapeutic and diagnostic potential |
Project in Poland financed by DG Regio |
Statements
3,257,316.34 zloty
0 references
4,252,710.24 zloty
0 references
76.59 percent
0 references
1 April 2017
0 references
31 March 2020
0 references
PURE BIOLOGICS SPÓŁKA AKCYJNA
0 references
51°7'34.7"N, 16°58'41.5"E
0 references
Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). Celem projektu "Usługowa platforma technologiczna do poszukiwania fragmentów przeciwciał o potencjale terapeutycznym i diagnostycznym” (dalej: Projekt) realizowanego przez Pure Biologics Sp. z o.o. jest opracowanie nowatorskiej platformy do poszukiwania i produkcji fragmentów przeciwciał w oparciu o technikę prezentacji fagowej (ang. phage display). W wyniku realizacji Projektu wdrożymy na rynek innowację produktową w postaci znacząco ulepszonej w stosunku do dostępnych rozwiązań usługi poszukiwania przeciwciał. Zdolność immunoglobulin do rozpoznawania szerokiej gamy antygenów sprawia, że znajdują się one w centrum rozwoju leków i diagnostyki medycznej. Przeciwciała precyzyjnie kierują się specyficznie do miejsca choroby, minimalizując efekty uboczne leczenia. Są również stosowane w testach diagnostycznych jako molekuły rozpoznające analit. Szybka diagnostyka pozwalająca monitorować stan pacjenta jest niezbędna w nowoczesnej medycynie. Liczba testów wykonywanych w domu lub w laboratorium stale rośnie, co przekłada się na wzrost popytu na nowe cząsteczki rozpoznające antygeny. Pure Biologics już w 2012 r. wdrożyła cieszącą się dużym zainteresowaniem platformę PureSelect do poszukiwania przeciwciał opartą o technikę prezentacji fagowej jako alternatywę dla immunizacji zwierząt. Zebrane przez lata doświadczenie pozwoliło zidentyfikować obszary wymagające ulepszenia, tak aby odpowiedzieć na zmieniające się zapotrzebowania rynkowe, i skłoniło nas do opracowania nowego produktu o zwiększonej funkcjonalności i skuteczności, który zapewni nam konkurencyjność i większy udziału w rynku. (Polish)
0 references
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The project “Service platform for the search for antibodies with therapeutic and diagnostic potential” (hereinafter:The project) implemented by Pure Biologics Sp. z o.o. is the development of an innovative platform for the production and production of antibodies based on phage display.As a result of the project, the product will be implemented in the market for product innovation which has been significantly improved in relation to the available solutions for the detection of antibodies.The capacity to recognise a wide range of antigens allows them to be at the centre of the development of medicines and medical diagnostics.Antibodies specifically address the disease location, minimising the side-effects of the treatment.They are also used in diagnostic tests as an analyte.Rapid diagnosis to monitor patient status is essential for modern medicine.The number of tests performed at home or in the laboratory is constantly increasing, which translates into increased demand for new molecules that recognise the antigens.The Pure Bioologtics already launched in 2012 the PureSelect Platform to seek antibody based on a phase presentation technique as an alternative to immunising animals.The experience gained over the years has identified areas for improvement in order to respond to changing market demands and has led us to develop a new product with increased functionality and efficiency that will ensure our competitiveness and market share. (English)
0 references
Identifiers
POIR.01.01.01-00-0749/16
0 references